GordonBCutlerJr.MD

Summary

• Dr. Cutler is a graduate of Harvard College and Harvard Medical School. He completed residency training in internal medicine (Barnes Hospital) and an endocrinology fellowship (National Institutes of Health). Gordon served as Senior Investigator (1978-1983) and Chief, Section on Developmental Endocrinology (1983-1997), at the NICHD. He then moved to Lilly Research Laboratories (1997-2008) as Medical Director and, later, Distinguished Medical Fellow. Since 2008, he has been an independent consultant to the pharmaceutical industry in clinical strategy and late-stage clinical trial design and execution. His professional interests have included disorders of growth, puberty, adrenal and parathyroid gland function, and diabetes. He has published over 290 peer-reviewed papers and trained numerous adult and pediatric endocrinologists. Dr. Cutler’s research led to FDA approval of histrelin (for precocious puberty) and ovine corticorelin (for differential diagnosis of Cushing syndrome), and to new FDA-approved indications for human growth hormone (for idiopathic short stature and SHOX gene deficiency). He led development strategy at Lilly for drugs targeting muscle (e.g., GH, GH secretagogue, SARM, and anti-myostatin), obtained US and EU regulatory advice on treatment of frailty, and co-authored a consensus report on designing RCTs for frailty in the elderly. He co-invented a novel, ultra-long-acting basal insulin (basal insulin peglispro, LY 2605541)—for which development was halted for business reasons after phase 3 clinical trials—and led the design of 9 phase 3 trials for Lilly’s inhaled insulin product, which was cancelled for commercialization risk. Gordon is a member of The Endocrine Society, ADA, ACP (Fellow), AMA, and AAAS. Honors include the US Public Health Service Commendation Medal, Outstanding Service Medal, and Meritorious Service Medal, and Lilly Research Laboratories President’s Award.